C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy
| العنوان: | C-Peptide Replacement Therapy and Sensory Nerve Function in Type 1 Diabetic Neuropathy |
|---|---|
| المؤلفون: | Jan Bolinder, Karin Ekberg, Christian Berne, John Wahren, Tom Brismar, Per Lindström, Hans J. Arnqvist, Bo-Lennart Johansson, Anders Norrby, Lisa Juntti-Berggren |
| المصدر: | Diabetes Care. 30:71-76 |
| بيانات النشر: | American Diabetes Association, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Diabetic neuropathy, Endocrinology, Diabetes and Metabolism, Neural Conduction, Peptide hormone, chemistry.chemical_compound, Diabetic Neuropathies, Double-Blind Method, Sural Nerve, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Age of Onset, Neurologic Examination, Sweden, Advanced and Specialized Nursing, Autoimmune disease, Type 1 diabetes, C-Peptide, C-peptide, business.industry, Patient Selection, Middle Aged, medicine.disease, Peripheral, Diabetes Mellitus, Type 1, Endocrinology, medicine.anatomical_structure, chemistry, business, Sensory nerve |
| الوصف: | OBJECTIVE—C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS—This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS—The age of the 139 patients who completed the protocol was 44.2 ± 0.6 (mean ± SE) years and their duration of diabetes was 30.6 ± 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 ± 0.08 SD below body height–corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide–treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide–treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 ± 0.1% at baseline) decreased slightly but similarly in C-peptide–and placebo-treated patients during the study. CONCLUSIONS—C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy. |
| تدمد: | 1935-5548 0149-5992 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d02ab3fe322f88608759de1ee837dcbTest https://doi.org/10.2337/dc06-1274Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9d02ab3fe322f88608759de1ee837dcb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|